Yuhan Corporation
Clinical trials sponsored by Yuhan Corporation, explained in plain language.
A South Korean pharmaceutical company developing drugs and vaccines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New generic combo pill for high blood pressure put to the test Results expected Sep 2026 (estimated)
- Healthy men needed to test experimental Drug's safety Results expected Mar 2027 (estimated)
- New drug YH32364 targets Hard-to-Treat cancers in first human trial Results expected Jun 2027 (estimated)
- New hope for chronic hives? experimental drug lesigercept enters Mid-Stage trial Results expected Jun 2027 (estimated)
-
New Triple-Drug combo aims to lower blood pressure better in seniors
Disease control OngoingThis study tests a new fixed-dose combination pill containing three blood pressure medicines (telmisartan, amlodipine, and chlorthalidone) against another triple combination (with hydrochlorothiazide instead of chlorthalidone) in elderly patients whose blood pressure is not well …
Phase 4 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Healthy men needed to test experimental Drug's safety
Knowledge-focused OngoingThis early-stage study tests the safety and how the body handles a new oral drug, YH35995, in 86 healthy adult men. Participants receive either the drug or a placebo, and researchers monitor side effects and drug levels in the blood. The goal is to gather safety information, not …
Phase 1 • Sponsor: Yuhan Corporation • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC